LSI announced that a domestic clinical trial for spinal cord injury in the subacute phase will be started using the Muse cell product “CL2020”.. The company has been conducting clinical trials already for three other diseases, acute myocardial infarction, cerebral infarction, and epidermolysis bullosa, and aims to apply for approval in 2020 and 2021 for […]
The Biopharmaceuticals sector in Japan: Government regulations, the competitive situation and how to find an entry point – A primer for European SMEs.
This report is accessible free of cost to EU companies which have registered to the “EU Business in Japan” website as a member via: http://www.eubusinessinjapan.eu/user/register Download the Table of Contents to this article